Michael J. Herling
Known title: DirectorCIK: 0001451824
Michael J. Herling's purchase track record
Michael J. Herling has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/19/2025 | BCO | $19K | +28.9% | +26.1% | +11.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| BCO | ▲ Buy | Grant | 160 | $0 | 10/1/2026 | View on chart |
| BCO | ▲ Buy | Grant | 171 | $0 | 7/1/2026 | View on chart |
| BCO | ▲ Buy | Option Exercise | 1,844 | $0 | 4/28/2026 | View on chart |
| BCO | ▲ Buy | Grant | 156 | $0 | 4/1/2026 | View on chart |
| BCO | ▲ Buy | Grant | 139 | $0 | 1/1/2026 | View on chart |
| BCO | ▲ Buy | Grant | 139 | $0 | 10/1/2025 | View on chart |
| BCO | ▲ Buy | Grant | 175 | $0 | 7/1/2025 | View on chart |
| BCO | ▲ Buy | Open Market | 222 | $19K | 5/19/2025 | View on chart |
| BCO | ▲ Buy | Option Exercise | 1,705 | — | 5/2/2025 | View on chart |
| BCO | ▲ Buy | Grant | 181 | $0 | 4/1/2025 | View on chart |
| BCO | ▲ Buy | Grant | 168 | $0 | 1/1/2025 | View on chart |
| BCO | ▲ Buy | Grant | 135 | $0 | 10/1/2024 | View on chart |
| BCO | ▲ Buy | Grant | 152 | $0 | 7/1/2024 | View on chart |
| BCO | ▲ Buy | Option Exercise | 2,402 | — | 5/2/2024 | View on chart |
| BCO | ▲ Buy | Grant | 169 | $0 | 4/1/2024 | View on chart |
| BCO | ▲ Buy | Grant | 177 | $0 | 1/1/2024 | View on chart |
| BCO | ▲ Buy | Grant | 215 | $0 | 10/1/2023 | View on chart |
| BCO | ▼ Sell | Gift | 1,818 | $0 | 9/12/2023 | View on chart |
| BCO | ▲ Buy | Grant | 230 | $0 | 7/1/2023 | View on chart |
| BCO | ▲ Buy | Option Exercise | 2,652 | — | 5/5/2023 | View on chart |
| BCO | ▲ Buy | Grant | 233 | $0 | 4/1/2023 | View on chart |
| BCO | ▼ Sell | Open Market | 3,089 | $206K | 3/6/2023 | View on chart |
| BCO | ▼ Sell | Gift | 1,714 | $0 | 3/6/2023 | View on chart |
| BCO | ▲ Buy | Grant | 290 | $0 | 1/1/2023 | View on chart |
| BCO | ▲ Buy | Grant | 322 | $0 | 10/3/2022 | View on chart |
| BCO | ▲ Buy | Grant | 257 | $0 | 7/1/2022 | View on chart |
| BCO | ▲ Buy | Option Exercise | 1,818 | — | 5/6/2022 | View on chart |
| BCO | ▲ Buy | Grant | 229 | $0 | 4/1/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Brink's Gets CMA Approval for NCR Atleos Deal Remedy
Brink's received acceptance in principle from the UK's CMA regarding a proposed remedy for its pending acquisition of NCR Atleos. The company also reported Q2 2026 results and confirmed that a potential sale of UK assets will not impact expected $200M in annual synergies. This regulatory progress is a key step in finalizing the transaction.
Brink's Gets CMA Approval for NCR Atleos Deal Remedy. Brink's received acceptance in principle from the UK's CMA regarding a proposed remedy for its pending acquisition of NCR Atleos. The company also reported Q2 2026 results and confirmed that a potential sale of UK assets will not impact expected $200M in annual synergies. This regulatory progress is a key step in finalizing the transaction.